Seeking Alpha
12 Sept 2026, 11:19 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
Tozorakimab showed a 29% to 34% reduction in COPD attacks across two large Phase III trials. — Positive Phase III results for a major indication typically drive significant valuation increases for pharmaceutical companies.
+0.60Tozorakimab demonstrated a 23% reduction in attacks among patients with low eosinophil counts, a segment poorly served by existing biologics. — Addressing an underserved patient niche expands the total addressable market and competitive advantage.
+0.40The failure of Wainua in July resulted in a market value loss of over $30 billion for AstraZeneca. — While a past event, it establishes a baseline of volatility and skepticism regarding the current pipeline's reliability.
-0.30Which stocks this story touches
Continue reading
5 related stories
Top 1 mover · tap to explore
While a previous failure caused significant losses, new Phase III trial results for tozorakimab show promising efficacy in a broad COPD market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
